Spero Therapeutics, Inc. (SPRO)
NASDAQ · Manufacturing · Pharmaceutical preparations
SPRO price, last 12 months
Key stats
- Previous close
- $1.25
- Open
- $1.23
- Day range
- $1.21 – $1.39
- 52-week range
- $1.08 – $3.08
- Volume
- 534.8K
- Avg volume (20 days)
- 774.1K
- Market cap
- $71.6M
Performance
Technicals and fundamentals
About Spero Therapeutics, Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $71.6M